KRAS and neoplasm: Next‐generation sequencing failed to detect mutations covering the hotspots in 22 tumour‐related genes, which included EGFR, ERBB2 and ERBB4 and their downstream effectors (KRAS, BRAF, PIK3CA, AKT1, PTEN, NRAS and MAPK).